Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in FGFR2-amplified gastric/GEJ cancer (China, phase II)
CTR20233585Phase 2Terminated
- Sponsor
- LianBio
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of infigratinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by LianBio. Started Nov 2023; status: terminated.
02
Drugs
infigratinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233585.